Key findings from these early studies included: Long half-life (~200300 hours): Tesofensine has an exceptionally long elimination half-life, allowing for once-daily oral dosing and stable plasma concentrations Dose-proportional pharmacokinetics: Blood levels increased predictably with dose across the 0.125 mg to 1.0 mg range Acceptable tolerability: The most common side effects were dry mouth, insomnia, nausea, and constipation consistent with its monoaminergic mechanism Cardiovascular signal: Dose-dependent increases in heart rate (typically 510 bpm) were observed, along with modest blood pressure changes at higher doses The Parkinson's disease Phase I/II trials were particularly informative
The New England journal of medicine , 384 (11), 9891002
Abstract Glucagon-like petide-1 (GLP-1) potentiates insulin and suppresses glucagon secretion from the pancreas in response to the ingestion of nutrients
They can provide proper diagnosis and guidance based on your individual health needs
[6] Crucially for weight management, these medications act on appetite-regulating centres in the hypothalamus, reducing hunger signals and increasing satiety